The changing landscape of gene editing in hematopoietic stem cells: a step towards Cas9 clinical translation
- 1 November 2017
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Hematology
- Vol. 24 (6) , 481-488
Abstract
Purpose of review: Since the discovery two decades ago that programmable endonucleases can be engineered to modify human cells at single nucleotide resolution, the concept of genome editing was born. Now these technologies are being applied to therapeutically relevant cell types, including hematopoietic stem cells (HSC), which possess the power to repopulate an entire blood and immune system. The purpose of this review is to discuss the changing landscape of genome editing in hematopoietic stem cells (GE-HSC) from the discovery stage to the preclinical stage, with the imminent goal of clinical translation for the treatment of serious genetic diseases of the blood and immune system. Recent findings: With the discovery that the RNA-programmable (sgRNA) clustered regularly interspace short palindromic repeats (CRISPR)-Cas9 nuclease (Cas9/sgRNA) systems can be easily used to precisely modify the human genome in 2012, a genome-editing revolution of hematopoietic stem cells (HSC) has bloomed. We have observed that over the last 2 years, academic institutions and small biotech companies are developing HSC-based Cas9/sgRNA genome-editing curative strategies to treat monogenic disorders, including β-hemoglobinopathies and primary immunodeficiencies. We will focus on recent publications (within the past 2 years) that employ different genome-editing strategies to ‘hijack’ the cell's endogenous double-strand repair pathways to confer a disease-specific therapeutic advantage. Summary: The number of genome-editing strategies in HSCs that could offer therapeutic potential for diseases of the blood and immune system have dramatically risen over the past 2 years. The HSC-based genome-editing field is primed to enter clinical trials in the subsequent years. We will summarize the major advancements for the development of novel autologous GE-HSC cell and gene therapy strategies for hematopoietic diseases that are candidates for curative allogeneic bone marrow transplantation.Keywords
This publication has 41 references indexed in Scilit:
- A Functional Element Necessary for Fetal Hemoglobin SilencingNew England Journal of Medicine, 2011
- Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector deliveryNature Biotechnology, 2007
- Therapeutic gene causing lymphomaNature, 2006
- Chimeric Nucleases Stimulate Gene Targeting in Human CellsScience, 2003
- Bcl11a is essential for normal lymphoid developmentNature Immunology, 2003
- A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined ImmunodeficiencyNew England Journal of Medicine, 2003
- Management of Sickle Cell DiseaseNew England Journal of Medicine, 1999
- Increased Fetal Hemoglobin in Patients Receiving Sodium 4-PhenylbutyrateNew England Journal of Medicine, 1992
- Bone-Marrow Transplantation in a Patient with Sickle-Cell AnemiaNew England Journal of Medicine, 1984
- IMMUNOLOGICAL RECONSTITUTION OF SEX-LINKED LYMPHOPENIC IMMUNOLOGICAL DEFICIENCYThe Lancet, 1968